Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) COO Joseph Schachle sold 4,697 shares of Opus Genetics stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $5.22, for a total transaction of $24,518.34. Following the completion of the transaction, the chief operating officer owned 296,084 shares in the company, valued at $1,545,558.48. This trade represents a 1.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Opus Genetics Price Performance
Shares of IRD opened at $5.12 on Tuesday. The company has a market capitalization of $365.57 million, a PE ratio of -6.24 and a beta of 0.52. Opus Genetics, Inc. has a one year low of $0.81 and a one year high of $5.81. The company's fifty day moving average price is $4.70 and its 200 day moving average price is $3.09.
Opus Genetics News Summary
Here are the key news stories impacting Opus Genetics this week:
- Neutral Sentiment: Management will present at several ophthalmology and industry conferences in May 2026, maintaining visibility with investors and the research community; this is routine corporate outreach rather than an immediate clinical readout. Opus Genetics to Participate in Leading Medical Conferences in May 2026
- Negative Sentiment: Multiple insiders sold stock on April 23rd (CEO George Magrath, CFO Robert Gagnon, COO Joseph Schachle, President Benjamin Yerxa, and others). Combined sales total tens of thousands of shares at roughly $5.18–$5.24 per share. While the company discloses these were sales to cover tax withholding on vested awards (reducing the likelihood of a signal of loss of confidence), clustered insider selling can pressure the share price and likely contributed to today's weakness. SEC filings: CEO sale CEO Form 4, CFO sale CFO Form 4, other insider filings available in SEC disclosures.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Occudo Quantitative Strategies LP bought a new position in shares of Opus Genetics during the 4th quarter worth about $25,000. Comerica Bank bought a new position in shares of Opus Genetics during the 1st quarter worth about $29,000. Virtu Financial LLC acquired a new stake in shares of Opus Genetics during the 4th quarter valued at about $34,000. Raymond James Financial Inc. boosted its position in shares of Opus Genetics by 95.6% during the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company's stock valued at $37,000 after acquiring an additional 11,000 shares in the last quarter. Finally, Johnson Investment Counsel Inc. acquired a new stake in shares of Opus Genetics during the 4th quarter valued at about $40,000. Institutional investors own 14.97% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms have issued reports on IRD. Oppenheimer began coverage on shares of Opus Genetics in a research report on Monday, March 16th. They issued an "outperform" rating and a $10.00 price target on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Opus Genetics in a report on Tuesday, April 21st. Lifesci Capital upgraded shares of Opus Genetics to a "strong-buy" rating in a report on Thursday, February 12th. Wall Street Zen upgraded shares of Opus Genetics from a "sell" rating to a "hold" rating in a report on Sunday, March 1st. Finally, Chardan Capital boosted their price objective on shares of Opus Genetics from $9.00 to $11.00 and gave the stock a "buy" rating in a report on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $10.11.
Get Our Latest Report on IRD
About Opus Genetics
(
Get Free Report)
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
